PIK3CB and cancer: The previous studies have exhibited that significant PI3K/AKT/mTOR axis is significantly altered in cancer and targeting this axis with multiple inhibitors can modulate a variety of cellular processes such as cell proliferation, autophagy, apoptosis, angiogenesis, EMT, and chemoresistance.